Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Carmat SA Obtains Approval to Proceed with Human Implantations of its Bioprosthetic Atificial Heart


Tuesday, 14 May 2013 12:30am EDT 

Carmat SA announced that it has obtained the approval of four cardiac surgery centers in Belgium, Poland, Saudi Arabia and Slovenia to proceed with the first clinical implantations of its bioprosthetic total artificial heart. These institutions are the St Pierre University Hospital (Brussels, Belgium), the Silesian Center for Heart Disease (Zabrze, Poland), the Prince Sultan Cardiac Center (Riyadh, Saudi Arabia), and the University Medical Centre Ljubljana (Ljubljana, Slovenia). 

Latest Developments for Carmat SA

Company Quote

70.75
0.25 +0.35%
6:54am EST